Unicorn Nest Logo

Brooks Hill Partners

www.brookshillpartners.com
Total investments

12

Average round size

1M

Portfolio companies

9

Rounds per year

1.50

Follow on index

0.25

Exits

3

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologySoftwareArtificial IntelligenceMachine LearningHealth CareManufacturingCloud ComputingLife SciencePharmaceuticalQuantum Computing

Investments analytics

Analytics

Total investments
12
Lead investments
0
Exits
3
Rounds per year
1.50
Follow on index
0.25
Investments by industry
  • Biotechnology (5)
  • Machine Learning (4)
  • Artificial Intelligence (4)
  • Health Care (4)
  • Pharmaceutical (3)
    • Show 19 more
Investments by region
  • United States (10)
  • Germany (2)
Peak activity year
2017
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.
Sign Up

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
108M
Group Appearance index
0.25
Avg. company exit year
6
Strategy success index
0.10

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Upgrade

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Astrocyte Pharmaceuticals 17 Jul 2017 Biotechnology, Pharmaceutical, Therapeutics, Clinical Trials Seed 2M United States, Massachusetts, Cambridge
Professional Credentials Exchange 12 Jul 2021 Software, Health Care, Marketplace, Blockchain Seed 4M United States, Florida, Tampa
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.